You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 21, 2024

Claims for Patent: 5,980,884

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,980,884

Title:	Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
Abstract:	Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.
Inventor(s):	Blatt; Larry (Boulder, CO), Klein; Michael (Thousand Oaks, CA)
Assignee:	Amgen, Inc. (Thousand Oaks, CA)
Application Number:	08/595,440
Patent Claims:	1. A method for retreating HCV patients, said patients having failed to respond to previous treatment with an interferon, comprising administering to a patient a therapeutically effective amount of interferon consensus. 2. A method according to claim 1, wherein said interferon consensus is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 3. A method according to claim 2, wherein said interferon consensus is IFN-con.sub.1. 4. A method according to claim 1 wherein said interferon consensus is a product of prokaryotic expression of an exogenous DNA sequence. 5. A method according to claim 1, wherein the therapeutically effective amount is administered orally, intravenously, intramuscularly, subcutaneously, intranasally, or intralesionally. 6. A method according to claim 1, wherein the therapeutically effective amount is 15 .mu.g administered subcutaneously three times weekly for 24 weeks. 7. A method for obtaining normalized serum alanine aminotransferase (ALT) levels in a patient suffering from HCV and having failed to respond to previous treatment with interferon therapy, comprising administering to said patient a therapeutically effective amount of interferon consensus.

Details for Patent 5,980,884

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	10/06/1997	⤷ Sign Up	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,980,884

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
South Africa	97721	⤷ Sign Up
World Intellectual Property Organization (WIPO)	9727866	⤷ Sign Up
Slovakia	101798	⤷ Sign Up
Norway	983410	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.